Collaboration

#Collaboration #Drug discovery #Mergers and acquisitions #Partnership

The new industry deals progressing drug discovery

New partnerships, acquisitions and collaborations are helping drug discovery companies to tackle some of the biggest problems facing the industry. These include patient access to cell and gene therapies, the development of DNA gene therapies, and the challenges surrounding GI clinical trials.  Delbert acquires injectable antibiotic from Bristol Myers Squibb… Read More

#Business & Investment #News

#Collaboration #Partnership

New DDW Highlights podcast: 17 February 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Love was in their air on Valentine’s Day as last week’s news round-up celebrated… Read More

#News

#Collaboration #Partnership

This week in drug discovery (10-14 February) 

News round-up for 10-14 February by DDW Senior Digital Content Editor Diana Spencer. Love is in their air this Valentine’s Day as this week’s news round-up celebrates the importance of collaboration in life sciences, whether that’s in the sharing of data, technology, or expertise. The top… Read More

#News

Female scientists working in a lab
#ABPI #Biopharmaceuticals #Collaboration #Pharmaceutical industry

Industry-academic collaborations vital for UK pharma workforce

A surge in apprenticeships, placements, and global research collaborations is strengthening the UK’s pharmaceutical workforce.  This is a summary of the key findings from the latest Industry and Academic Links Survey from the Association of the British Pharmaceutical Industry (ABPI).  As National Apprenticeship Week (10-14 February) begins, new figures highlight… Read More

#Business & Investment #News

European Union and African Union flags
#Biologics #Collaboration #Immunology / Virology & Vaccines #mRNA-based vaccines #RNA

African European alliance to advance RNA-based vaccines

A new African European collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines.  A Memorandum of Understanding was signed by Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences during the… Read More

#News

#Antibodies #Autoimmune disease #Collaboration #FcR Therapeutics #Grifols #Nanobodies

Partners to target autoimmune Fc receptors using nanobodies

Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases.  The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that… Read More

#Business & Investment #News

Brain Awareness Week
#Artificial intelligence (AI) #Collaboration #Mergers and acquisitions #Partnership

Seven new drug discovery deals powered by AI

1 Servier and Google Cloud Servier and Google Cloud have announced an expanded five-year partnership focused on using AI and generative AI (gen AI) to accelerate the research and development (R&D) of innovative therapeutic solutions for patients.  According to Servier, by analysing large amounts of medical data in real time,… Read More

#Business & Investment #Editor's Choice #News

NVIDIA office Paris
#Artificial intelligence (AI) #Collaboration #NVIDIA #Partnership

NVIDIA expands AI life sciences partnerships

NVIDIA has announced new partnerships with IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, to accelerate drug discovery, enhance genomic research and pioneer advanced healthcare services.  The projects include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to… Read More

#Business & Investment #News

#Cancer drug targets #Collaboration #Drug discovery #Molecular glue degrader #Protein #Rappta Therapeutics #SpringWorks Therapeutics

License agreement for molecular glue targeting PP2A

Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More

#Business & Investment #Cancer Research #News

#Alchemab Therapeutics #Amyotrophic lateral sclerosis (ALS) #Collaboration #Eli Lilly

Lilly and Alchemab collaborate on novel therapies for ALS 

Eli Lilly and Alchemab Therapeutics hope to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS) as part of a new research collaboration.  Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.   The company believes these antibodies,… Read More

#Business & Investment #News

#Collaboration #Gene therapy #Lipid based nanoparticle (LNP) #Orna Therapeutics #Vertex

Vertex signs multimillion dollar deal with Orna Therapeutics

Vertex Pharmaceuticals and Orna Therapeutics have announced plans to partner on gene therapies for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).  The three-year strategic research collaboration will utilise Orna’s lipid nanoparticle (LNP) delivery solutions.  In return Orna will receive upfront payments of $65 million, including an investment in… Read More

#Business & Investment #News #Trending News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Innovent #Lung cancer #Oncology #Roche #Small cell lung cancer

Roche pays $80 million for Innovent’s lung cancer ADC

Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer.  Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take over full development.  … Read More

#Business & Investment #News

#Collaboration #Deep Science Ventures #Fibrosis #Finance #General Inception #Therapeutics

Venture partners create fibrosis-focused therapeutics company

Venture studios Deep Science Ventures and General Inception have announced plans to create a company focused on developing novel treatments for fibrosis. Science Ventures and General Inception’s European arm, Igniter Europe, aim to establish a company dedicated to overcoming current bottlenecks in fibrosis therapeutics by developing a novel concept and… Read More

#Business & Investment #News

#Alzheimer's #Collaboration #GSK #Muna Therapeutics #Neuroscience #Transcriptomics

GSK and Muna ally on novel treatments for Alzheimer’s disease

GSK and biotechnology company Muna Therapeutics have entered a research alliance to identify and validate novel drug targets for the treatment of Alzheimer’s disease.   The companies will explore insights from Muna’s MiND-MAP platform, which applies spatial transcriptomics to brain samples from Alzheimer’s disease patients, cognitively resilient individuals, healthy controls, and… Read More

#Business & Investment #News

#Collaboration #Drug development #Drug discovery #Partnership

Nine collaborations driving drug discovery forward in Q4

Diana Spencer compiles a list of the research partnerships that will have a significant impact on the development of new drugs into 2025. Dutch Oncode Institute and Cancer Research Horizons The Dutch Oncode Institute and Cancer Research Horizons formed a strategic alliance during a recent Dutch economic mission to the… Read More

#Business & Investment #News

#Collaboration #Genomics #Genomics England #NHS #Public health #Research #Revvity

Collaboration to advance UK genomics research 

Revvity has announced an expansion of its working relationship with Genomics England that leverages both organisations' expertise and resources to advance critical genomic initiatives across the United Kingdom.   Building on the parties’ long and productive work history, this collaboration is dedicated to accelerating Genomics England’s research programmes, supporting diverse areas… Read More

#Business & Investment #News